Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer

Authors

  • Lars Ottestad Department of Oncology, Østfold Hospital Trust, Kalnes, Norway
  • Line Fronth Department of internal medicine, Vestre Viken, Bærum Hospital, Gjettum, Norway
  • Sajitha Rajendiran Førde Central Hospital, Førde, Norway
  • Liv Hege Aksnes Department of Internal Medicine, Vestre Viken, Ringerike Hospital, Hønefoss, Norway
  • Hans Petter Eikesdal Department of Oncology, Haukeland University Hospital, Bergen, Norway
  • Egil Støre Blix Institute of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway; ;Department of Oncology, University Hospital of North Norway, Tromsø, Norway
  • Marianne Ewertz Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

DOI:

https://doi.org/10.1080/0284186X.2019.1566771

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2019-03-04

How to Cite

Ottestad, L. ., Fronth, L. ., Rajendiran, S. ., Hege Aksnes, L. ., Petter Eikesdal, H. ., Støre Blix, E. ., & Ewertz, M. . (2019). Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Acta Oncologica, 58(3), 385–387 |. https://doi.org/10.1080/0284186X.2019.1566771

Issue

Vol. 58 No. 3 (2019): Acta Oncologica

Section

Articles